ABSTRACT
barriers to control, such as comorbidities, smoking, under-treatment, and suboptimal inhaler technique. Achieving asthma control is also hindered by perceptual barriers, contributing to reduced patient adherence to treatment regimens [8, 9] . Studies have suggested that therapies with a rapid onset of bronchodilation may encourage adherence and, thus, improve real-world asthma outcomes [10, 11] .
An additional ICS/LABA combination has been developed for the treatment of asthma. It combines the potent ICS, fluticasone propionate (fluticasone) [3, 12] , with the rapid-acting LABA, formoterol fumarate (formoterol) [13, 14] , in a single hydrofluoroalkane aerosol inhaler (fluticasone/formoterol; flutiform ® ; registered trademark of Jagotec AG, Muttenz, Switzerland, which is used under licence). The inclusion of formoterol in this combination would be expected to produce a rapid-onset bronchodilatory effect [13, 14] . Formoterol has been shown to reverse methacholine-induced severe bronchoconstriction more rapidly than salmeterol xinafoate (salmeterol) and as rapidly as the shortacting beta 2 -agonist, salbutamol [13, 15] . 
INTRODUCTION
Asthma is one of the most common chronic diseases in the world, and is associated with substantial direct and indirect healthcare costs, as well as significant morbidity and mortality [1, 2] .
The combination of an inhaled corticosteroid (ICS) and a long-acting beta 2 -agonist (LABA) is a highly efficacious treatment option for asthma, and is advocated by treatment guidelines for use in patients whose asthma is not controlled with an ICS alone [3] . Indeed, data from randomized clinical trials suggest that asthma control can be achieved with ICS/LABA therapy in the majority of patients [4, 5] .
Despite the availability of several ICS/LABA combination therapies, many patients in the real world have suboptimal asthma control [6, 7] . This may reflect the presence of practical and physical
Patients
Men and women (≥18 years old) with a history of mild-to-moderate-severe persistent asthma for at least 6 months before screening were eligible for inclusion in this study.
Patients were also required to have an FEV 1 of ≥40-≤85% of predicted normal values following appropriate withholding of asthma medications.
In addition, patients had to show reversibility in 
Study Treatments
Patients were randomly assigned 
MATERIALS AND METHODS
Full details on the methodology of this study (including further information on inclusion and exclusion criteria, the randomization procedure and dose allocation, study assessments, and statistical analyses) have been published previously [16] . The details relevant to this post-hoc analysis are presented briefly here.
Study Design
This 
Statistical Analyses
In the original, pre-planned study analysis, the onset of bronchodilation was assessed for the intention-to-treat (ITT) population 
RESULTS

Study Population
The ITT population comprised 202 patients. The demographics and asthma characteristics of the two treatment groups were similar at screening (Table 1) 
Onset of Bronchodilation
Fluticasone/formoterol treatment provided a faster onset of bronchodilation than fluticasone/salmeterol therapy on day 0, and this effect was maintained at the end of the study. On day 0, fluticasone/formoterol was superior to fluticasone/salmeterol for onset of bronchodilation over the first 120 min post-dose (HR = 1.47; 95% CI 1.05-2.05). Figure 1a shows the Kaplan-Meier plot for the onset of bronchodilation on day 0 (as published previously [16] ). Similarly, a significantly more rapid onset of bronchodilation with fluticasone/ formoterol was observed on day 84 (HR = 1.77; 95% CI 1.14-2.73; Fig. 1b) .
Responder rates were greater with fluticasone/ formoterol than with fluticasone/salmeterol within 5 min and within 120 min post-dose on day 0 and day 84 (Table 2) . On day 0, the odds of a patient "responding to treatment" and twofold higher within 120 min post-dose (OR = 2.03; 95% CI 1.07-3.89). Moreover, on day 84, the odds of a patient responding within 5 min post-dose were almost 10-fold higher with fluticasone/formoterol than with fluticasone/ salmeterol (OR = 9.58; 95% CI 2.14-42.90) and nearly twofold higher within 120 min post-dose (OR = 1.93; 95% CI 1.08-3.43; Table 2 ).
Changes in FEV 1
Fluticasone/formoterol provided more rapid HRs are from post-hoc analyses. Onset of bronchodilation was defined as the first post-dose time point at which FEV 1 was at least 12% greater than the pre-dose value. This figure is modified from [16] This is important because evidence shows that patients prefer asthma maintenance medication when they are satisfied with how quickly they can feel it beginning to work [10] . Indeed, a group of patients who were nonadherent to their controller medications cited being able to feel a medication working soon after administration as a factor that could improve their adherence [22] .
In real-world clinical practice, many patients with asthma remain uncontrolled [23] abilities to perform morning activities [29] .
In conclusion, these post-hoc analyses have provided strong additional evidence that fluticasone/formoterol has a more rapid onset of bronchodilation than fluticasone/salmeterol. 
